Cargando…

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma

The TP53 gene is the most commonly mutated gene in human cancers and mutations in TP53 have been shown to have either gain-of-function or loss-of-function effects. Using the data generated by The Cancer Genome Atlas, we sought to define the spectrum of TP53 mutations in hepatocellular carcinomas (HC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kancherla, Venkatesh, Abdullazade, Samir, Matter, Matthias S., Lanzafame, Manuela, Quagliata, Luca, Roma, Guglielmo, Hoshida, Yujin, Terracciano, Luigi M., Ng, Charlotte K. Y., Piscuoglio, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801302/ https://www.ncbi.nlm.nih.gov/pubmed/29456550 http://dx.doi.org/10.3389/fgene.2018.00002

Ejemplares similares

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

The Role of Long Non-Coding RNAs in Hepatocarcinogenesis
por: Lanzafame, Manuela, et al.
Publicado: (2018)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

How TP53 (almost) became an oncogene
por: Weinberg, Robert A
Publicado: (2019)

The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models
por: Ramelow, Julian, et al.
Publicado: (2020)

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis
por: Taha-Mehlitz, Stephanie, et al.
Publicado: (2021)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo‐Independent Regulation of Heat Shock Protein 70 Family Members
por: Coto‐Llerena, Mairene, et al.
Publicado: (2021)

Colitis Is Associated with Loss of the Histidine Phosphatase LHPP and Upregulation of Histidine Phosphorylation in Intestinal Epithelial Cells
por: Linder, Markus, et al.
Publicado: (2023)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens
por: Montazeri, Hesam, et al.
Publicado: (2021)

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
por: Versemann, Lennart, et al.
Publicado: (2022)

Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors
por: Blumer, Tanja, et al.
Publicado: (2019)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53
por: Liu, Shaoxian, et al.
Publicado: (2018)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models()
por: Andreozzi, Mariacarla, et al.
Publicado: (2016)

PFKFB4 Drives the Oncogenicity in TP53-Mutated Hepatocellular Carcinoma in a Phosphatase-Dependent Manner
por: Kam, Charles Shing, et al.
Publicado: (2023)

Prognostic gene signature profiles of hepatitis C-related early-stage liver cirrhosis
por: Venkatesh, Anu, et al.
Publicado: (2014)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion
por: Guo, Alvin Kunyao, et al.
Publicado: (2020)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
por: Luo, Ming, et al.
Publicado: (2023)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
por: Lehmann, Brian David, et al.
Publicado: (2015)

Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
por: Burmeister, Katharina, et al.
Publicado: (2017)

Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731]()
por: Andreozzi, Mariacarla, et al.
Publicado: (2020)

Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation
por: Yeo, Shi Yun, et al.
Publicado: (2016)

The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
por: Sabapathy, Kanaga
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oo0ffkl3oi0pg3967maln9l5mj